A Phase 3, Open-label, Long-term Study to Evaluate the Safety, Tolerability, and Analgesic Efficacy of BEMA Buprenorphine in Subjects With Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time

Trial Profile

A Phase 3, Open-label, Long-term Study to Evaluate the Safety, Tolerability, and Analgesic Efficacy of BEMA Buprenorphine in Subjects With Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Back pain; Musculoskeletal pain; Neuropathic pain
  • Focus Adverse reactions; Registrational
  • Sponsors Endo Pharmaceuticals
  • Most Recent Events

    • 03 Jun 2016 New data will be presented during a poster session at the International Conference on Opioids (ICOO 2016) in Boston, as per Endo Pharmaceuticals media release.
    • 03 Jun 2016 Results published in Endo Pharmaceuticals media release.
    • 17 Nov 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top